Assessment of the effectiveness of Budesonide MMX^® for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study.

ABSTRACT:

Introduction

Budesonide MMX^® is approved for induction of remission in mild-to-moderate active ulcerative colitis (UC) in adults in whom 5-ASA is not sufficient. There is a lack of data on its effectiveness and safety in clinical practice.

Material and methods

The CORE Practice study was a multi-centre prospective, observational study of mild-to-moderate UC-patients treated with Budesonide MMX^® 9 mg for up to 8 weeks (induction). Enrolled patients had previously been prescribed Budesonide MMX^® 9 mg in accordance with the SmPC within a 5-day time window. The primary endpoint was the percentage of patients achieving a decrease ≥ 3 points in the UCDAI clinical sub-score at the end of the induction treatment. Other endpoints were clinical remissi

SUBMITTER: Jesionowski M 

PROVIDER: S-EPMC10395053 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature